Thyrotropin Alpha
- Atc Codes:H01AB01#V04CJ01
- CAS Codes:194100-83-9
- PHARMGKB ID:194100-83-9
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Thyrogen; Belgium: Thyrogen; Bulgaria: Thyrogen; Cyprus: Thyrogen; Czech Republic: Thyrogen; Denmark: Thyrogen; Estonia: Thyrogen; Finland: Thyrogen; France: Thyrogen; Germany: Thyrogen; Greece: Thyrogen; Hungary: Thyrogen; Ireland: Thyrogen; Italy: Thyrogen; Latvia: Thyrogen; Lithuania: Thyrogen; Luxembourg: Thyrogen; Malta: Thyrogen; Netherlands: Thyrogen; Poland: Thyrogen; Romania: Thyrogen; Slovakia: Thyrogen; Slovenia: Thyrogen; Spain: Thyrogen; Sweden: Thyrogen; UK: Thyrogen.
North America
Canada: Thyrogen; USA: Thyrogen.
Drug combinations
Chemistry
Thyrotropin Alpha: C~1039~H~1602~N~274~O~307~S~27~. Mw: 23709.28; C~437~H~682~N~122~O~134~S~13~ (α-subunit). Mw: 10205.69; C~602~H~920~N~152~O~173~S~14~ (β-subunit). Mw: 13503.59. Recombinant form of human, thyroid stimulating hormone (rhTSH). RhTSH is produced by mammalian cell culture technology using a Chinese Hamster Ovary (CHO) cell line. A CHO cell line was co-transfected with two recombinant plasmids containing respectively the DNA coding sequences of the α and β subunits of TSH. Thyrotropin (human β-subunit protein moiety), complex with chorionic gonadotropin (human α-subunit protein moiety). CAS-194100-83-9 (1997).
Pharmacologic Category
Diagnostic Agents; Thyroid Function. (ATC-Code: H01AB01; V04CJ01).
Mechanism of action
Derived from a recombinant DNA source, it has identical amino acid sequence to endogenous human thyroid stimulating hormone (TSH). As a diagnostic tool in conjunction with serum thyroglobulin (Tg) testing, thyrotropin-α stimulates secretion of Tg from any remaining thyroid tissues (remnants). As adjunctive agent for radioiodine ablation treatment of thyroid cancer tissue remnants, thyrotropin-α binds to TSH receptors on these tissues, stimulating uptake and organification of iodine, including radiolabeled iodine (^131^I). Cancerous tissue destroyed via γ-emission from radioiodine concentrated in these tissues.
Therapeutic use
Adjunctive diagnostic tool for serum thyroglobulin testing. Adjunctive treatment for radioiodine ablation of thyroid tissue remnants after total or near-total thyroidectomy in well-differentiated thyroid cancer without evidence of metastatic disease.
Pregnancy and lactiation implications
Effects on fetus or pregnant woman unknown. Excretion in breast milk unknown (use with caution in lactation).
Unlabeled use
Contraindications
Warnings and precautions
Caution when administered to patients previously treated with bovine TSH and, in particular, to those who have experienced hypersensitivity reactions to bovine TSH. Use with caution in extensive metastatic disease (may cause edema and/or hemorrhage at metastatic sites, leading to impingement of vital anatomic structures). Thyrotropin-α elimination is significantly reduced in dialysis-dependent end-stage renal impairment, leading to prolonged elevation of thyroid-stimulating hormone levels. Use with caution in known history of heart disease in presence of significant residual thyroid tissue. Thyrotropin-induced hyperthyroidism may lead to serious cardiovascular complications. Use with caution in significant residual thyroid tissue (will cause significant increases in thyroid hormone levels), and in serious underlying illness in the presence of significant residual thyroid tissue (thyrotropin-induced hyperthyroidism may lead to serious complications).